Summary & Overview
HCPCS G2182: First-Time Biologic or Immune Response Modifier Therapy Initiation
HCPCS Level II code G2182 denotes initiation of biologic or immune response modifier therapy for patients and is used to identify the first-time administration and associated management. This designation matters nationally as biologic therapies are increasingly common across immunology, oncology, and specialty care, and accurate coding affects claims processing, utilization tracking, and clinical continuity. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn how G2182 is defined, the clinical and service contexts in which it is used, and what typical sites of service are associated with first-time biologic therapy initiation. The publication outlines common billing modifiers and payer coverage considerations where available, summarizes relevant policy updates affecting first-dose and initiation coding, and describes operational implications for infusion centers and outpatient clinics. It also highlights areas where input data is not available, such as associated taxonomies, specific ICD-10 diagnoses, and related service line details. This resource is intended to provide clinicians, coders, and billing professionals with a concise reference on the purpose and practical use of HCPCS Level II code G2182 in the national billing landscape.
Billing Code Overview
HCPCS Level II code G2182 represents a patient receiving first-time biologic and/or immune response modifier therapy. This code is used to identify the initiation of biologic or immune response modifier treatment for a patient.
Service Type
- Infusion/administration initiation and first-time biologic therapy management
Typical Site of Service
- Infusion center, outpatient clinic, or hospital outpatient department where biologic or immune response modifier therapies are first administered and managed.
Clinical & Coding Specifications
Clinical Context
A 48-year-old patient with moderate-to-severe plaque psoriasis presents to a specialty infusion clinic for initiation of first-time biologic therapy with an interleukin inhibitor. After evaluation by the dermatology team, baseline labs (CBC, CMP, hepatitis B/C testing, TB screening) and vaccination review are completed. The patient receives education on expected effects and adverse events, signs of infection, and infusion or injection technique. The biologic is administered via subcutaneous injection or clinic-supervised infusion depending on the agent. Observation for immediate hypersensitivity or infusion-related reactions is performed for 30–60 minutes. Documentation includes indication, prior treatment failures or contraindications to non-biologic agents, informed consent for biologic therapy, lot number and expiration of the biologic, route and dose given, and time-in/time-out for infusion procedures. Subsequent scheduling of maintenance dosing and monitoring plan is recorded in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or intensity substantially exceeds usual for administration or counseling related to initiating biologic therapy. |
23 |